Typhoid fever: issues in laboratory detection, treatment options & concerns in management in developing countries. (26th June 2018)

• Record Type: Journal Article
• Authors: Veeraraghavan, Balaji; Pragasam, Agila K; Bakthavatchalam, Yamuna D; Ralph, Ravikar
• Is Part Of: Future science OA. Volume 4:Number 6(2018)
• Publication Date: 2018-06-26
• Subjects: azithromycin -- cefixime -- ceftriaxone -- Salmonella Typhi; Medicine -- Periodicals; Biotechnology -- Periodicals; 610
• DOI: 10.4155/fsoa-2018-0003
• Languages: English
• ISSNs: 2056-5623

Abstract

Multidrug-resistant Salmonella enterica subsp. enterica serovar Typhi (resistant to ampicillin, chloramphenicol and cotrimoxazole), was significantly reduced with the increased usage of fluoroquinolones and azithromycin. This has led to declining multidrug resistance rates in India with increasing ciprofloxacin nonsusceptibility rates and clinical failures due to azithromycin. However, for the available agents such as ceftriaxone, azithromycin and fluoroquinolones, the dose and duration for treatment is undefined. The ongoing clinical trials for typhoid management are expected to recommend the defined dose and duration for better clinical outcome. We made an attempt to summarize the issues in laboratory detection, treatment options and responses, and the concerns in clinical practice seen in the developing countries. Lay abstract: Typhoid fever is an important cause of mortality in developing countries and is a major public health concern. Cephalosporins or azithromycin are the drugs of choice for treating infection caused by the reduced fluoroquinolone susceptibility of S. Typhi. Emergence of cephalosporin resistance in S. Typhi and azithromycin-associated clinical and microbiological failure is of significant concern in developing countries. An approach of cephalosporin–azithromycin combination therapy has been suggested, which could be a potential alternative in treating uncomplicated S. Typhi infection in endemic areas. This review summarizes the field so far.